Drug Profile

BMC 128

Alternative Names: BMC-128; LS-LBP-002

Latest Information Update: 13 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biomica
Class Antineoplastics; Bacteria; Immunotherapies
Mechanism of Action Bacteria replacements; Microbiome modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma

Most Recent Events

04 Feb 2026 Evogene plans to advance regulatory filings in China and the United States for commercialization
04 Feb 2026 BMC128 is still in phase I trial for Renal cell carcinoma and Non-small cell lung cancer in Isreal
04 Feb 2026 BMC 128 licensed to Lishan Biotech worldwide

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com